FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1527-1529 October 6, 2005 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Avorn, J. PubMed Citation

To the Editor: Avorn's proposal in his Perspective article (June 23 issue)¹ that the combination of torcetrapib and atorvastatin is market-driven, undermining its usefulness, is baseless. The program does not extend the patent on atorvastatin. Its basic aim is to provide efficiently the greatest medical benefit to the most patients while maintaining the greatest likelihood of success.

Mandatory control of low-density lipoprotein (LDL) cholesterol is a foundation of treatment for patients who are at increased risk for heart disease, including those with isolated low levels of high-density lipoprotein (HDL) cholesterol.² Torcetrapib alone at the dose used in phase 3 studies . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.